Analysts Set Metagenomi, Inc. (NASDAQ:MGX) Price Target at $21.40

Metagenomi, Inc. (NASDAQ:MGXGet Free Report) has received a consensus rating of “Buy” from the six ratings firms that are covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $21.40.

Several research analysts recently weighed in on the stock. BMO Capital Markets assumed coverage on shares of Metagenomi in a report on Tuesday, March 5th. They issued an “outperform” rating and a $22.00 target price for the company. TD Cowen began coverage on shares of Metagenomi in a report on Tuesday, March 5th. They issued an “outperform” rating for the company. Jefferies Financial Group began coverage on shares of Metagenomi in a report on Tuesday, March 5th. They set a “buy” rating and a $23.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of Metagenomi in a report on Tuesday, March 5th. They set an “overweight” rating and a $16.00 price objective for the company. Finally, Chardan Capital reissued a “buy” rating and set a $21.00 price objective on shares of Metagenomi in a report on Thursday, March 28th.

Get Our Latest Stock Report on MGX

Insider Activity at Metagenomi

In other Metagenomi news, major shareholder Holdings A/S Novo purchased 100,000 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was purchased at an average price of $10.25 per share, with a total value of $1,025,000.00. Following the acquisition, the insider now owns 100,000 shares in the company, valued at $1,025,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Metagenomi Stock Performance

Shares of Metagenomi stock opened at $10.49 on Friday. Metagenomi has a fifty-two week low of $9.74 and a fifty-two week high of $12.74.

Metagenomi Company Profile

(Get Free Report

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.

See Also

Analyst Recommendations for Metagenomi (NASDAQ:MGX)

Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.